Viruses (Nov 2022)

Antiviral Potential of Natural Resources against Influenza Virus Infections

  • Johanna Eichberg,
  • Elena Maiworm,
  • Markus Oberpaul,
  • Volker Czudai-Matwich,
  • Tim Lüddecke,
  • Andreas Vilcinskas,
  • Kornelia Hardes

DOI
https://doi.org/10.3390/v14112452
Journal volume & issue
Vol. 14, no. 11
p. 2452

Abstract

Read online

Influenza is a severe contagious disease caused by influenza A and B viruses. The WHO estimates that annual outbreaks lead to 3–5 million severe infections of which approximately 10% lead to the death of the patient. While vaccination is the cornerstone of prevention, antiviral drugs represent the most important treatment option of acute infections. Only two classes of drugs are currently approved for the treatment of influenza in numerous countries: M2 channel blockers and neuraminidase inhibitors. In some countries, additional compounds such as the recently developed cap-dependent endonuclease inhibitor baloxavir marboxil or the polymerase inhibitor favipiravir are available. However, many of these compounds suffer from poor efficacy, if not applied early after infection. Furthermore, many influenza strains have developed resistances and lost susceptibility to these compounds. As a result, there is an urgent need to develop new anti-influenza drugs against a broad spectrum of subtypes. Natural products have made an important contribution to the development of new lead structures, particularly in the field of infectious diseases. Therefore, this article aims to review the research on the identification of novel lead structures isolated from natural resources suitable to treat influenza infections.

Keywords